LRI Emergency Department and Children's Hospital

The Management of the Child with Petechia or a Non-Blanching Rash in the Emergency Department & Children's Hospital

Staff relevant to:	Health-care professionals engaged in the acute care of children in the ED, Children's Hospital and UCC
Team approval date:	April 2024
Version:	1
Revision due:	October 2025
Written by:	Shane Fitzgerald Paediatric Education OOPE
Trust Ref:	D2/2024

Contents

1. Introduction and Who Guideline applies to

Aim

To provide guidance to clinicians on the management of children with a non-blanching rash (NBR) presenting to hospital.

Target Patient Population

This evidence summary applies to children presenting with a Non-blanching rash (NBR) to the Emergency Department (ED) and Urgent Care Centre's (UCC).

Target Users

This guide is directed at health-care professionals engaged in the acute care of children in the ED, and UCC.

2. Background & guideline standards

NBR is a term for any rash in which the colour is unchanged with direct pressure. The term NBR is usually used in reference to petechiae or purpura (picture 1 & 2), and in this form it is a relatively common presentation to the emergency department (ED), accounting for around 2% of all attendances. [1,2]

Picture 1:

- **Petechia (<2mm)**



Picture 2:

- **Purpura (2-10mm)**
- **Ecchymoses (>10mm)**



The presence of a NBR is of concern to both parents and clinicians as it is associated with a wide range of underlying diagnoses, some of which are life-threatening. Any serious bacterial infection (SBI) can result in a NBR via disseminated intravascular coagulation (DIC). Some infections, however, feature a NBR as an early sign. The most common infections associated with a NBR as an earlier sign are as follows. [1-6]

Viral

- Enterovirus & adenovirus [3]

Bacterial

- Streptococcal infections [1-4]
- Meningococcal disease (1% of cases of fever and NBR presenting to the ED) [6]

Mechanical causes

Mechanical causes are identified in almost a quarter of paediatric NBR with straining, coughing or vomiting being most common. This causes transient raised pressure within the superior vena cava (SVC), with consequent petechiae in the distribution of the superior vena cava (SVC) alone (above the nipple line) [1]. Direct trauma can result in bruising that can be mistaken for a NBR. Typically there is a clear history of trauma, if a child is bruised without a clear and reasonable explanation then non-accidental injury should be considered and the child's case discussed with a senior clinician.

Vasculitic causes

Henoch-Schonlein Purpura (HSP) is the most common vasculitic cause of paediatric NBR, with other less common causes including atypical Kawasaki disease, polyarteritis nodosa and anti-neutrophil cytoplasmic antibody-related vasculitis. HSP typically presents with palpable purpura found in a gravity dependent distribution - classically on the legs and buttocks. [7]

Please refer to - **Henoch Schonlein Purpura HSP UHL Childrens Medical Guideline**

Haematological causes

The main haematological causes are thrombocytopenia, leukaemia and coagulopathy. Immune thrombocytopenia (ITP) is the most common haematological cause and presents with the sudden development of a NBR. In ITP, a full blood count (FBC) should show isolated thrombocytopenia, and a blood film should be normal other than thrombocytopenia. Other rare causes of thrombocytopenia include: [9,10]

- Infection (e.g., Epstein-Barr virus) [11]
- Drug induced (i.e. vaccination, heparin, non-steroidal anti-inflammatory drugs, ranitidine) [12-14]
- Thrombotic thrombocytopenic purpura
- DIC
- Hypersplenism
- Bone marrow failure

Undiagnosed haematological malignancies can present with a NBR, either as an isolated finding or in conjunction with other features such as weight loss, fatigue, pallor and general malaise. [13,15] Clinical features such as lymphadenopathy,

hepatomegaly, splenomegaly, jaundice and anaemia should be sought; [12] and any patient with an abnormal blood film or deficiencies in multiple cell lines should be discussed with the paediatric haematology service.

Coagulopathy is an exceptionally rare cause of paediatric NBR in children (<0.01% of cases). [16] A family history of coagulation disorders or a long history of easy bruising may warrant further investigation.

Other causes

It is worth considering whether a well-child's rash is in fact a normal variant. A study of infants attending routine health checks found that petechiae were commonly identified in well infants with over one-quarter having one or more petechiae. [17]

Remember

- The majority of children with a NBR have no cause identified - the NBR is presumed to be secondary to a viral infection [2]
- The incidence of meningococcal disease in children presenting with fever and NBR is about 1%, however recognition and early treatment of the child with meningococcal disease is paramount [16]
- Clinical signs and laboratory investigations can help guide your management

2.1 Assessment

Perform a global assessment of the child to assess wellness, nature and distribution of the rash and features of specific diseases.

The presence of purpura (>2mm) **or** appearing unwell **or** hypotensive shock **or** meningism confer a significant risk of invasive meningococcal disease or invasive bacterial infection. These children require immediate investigation and treatment for suspected sepsis/meningitis.

In addition to this immediate assessment the child should have a full clinical examination including measurement of vital signs (heart rate, respiratory rate, oxygen saturations, capillary refill time and blood pressure).

2.2 Management of Petechia & Non-blanching Rash



Suspected invasive bacterial infection, meningitis or meningococcal disease

- Please refer to - **Sepsis UHL Childrens Hospital Guideline**

The Child with an alternate diagnosis (i.e. mechanical cause, localised skin infection, eczema)

- Treat underlying cause

The well child with a NBR but no alternative diagnosis

- Well children with a NBR but no alternative diagnosis should have blood tests (which may include an FBC, U&E, CRP, blood culture, Meningococcal PCR as well as a **minimum 4 hours observation from the onset of the rash.** This is because children with Meningococcal disease usually become sick within hours of the onset of their petechial rash.

Such well children who require a blood test may be suitable for discharge home with clear safety-net advice only if:

1. **They remain well during their observation period (clinically well with normal Obs)**
2. **Their blood tests are reassuring: CRP <20mg/L with no raised inflammatory markers & no signs of haematological malignancy**
3. **No significant spread of the rash after 4 hours observation from the onset of the rash**
4. **No new purpura**

2.3 Special Considerations

Pre-hospital Antibiotic Administration:

- Any child who received pre-hospital **IM antimicrobials (i.e. IM benzylpenicillin or ceftriaxone) from a primary care doctor** prior to attending the emergency department but appears well on arrival should have blood tests performed including **blood gas, FBC, U&E, CRP, Blood culture & admission** pending results **+/- antibiotics** depending on clinical concern.

Parental Concern and safety-net advice

- Always address the parents and caregivers concerns
- When discharging a child home after a period of observation it is important that the patents are involved in the shared decision making process and understand when to return if the clinical picture changes

- Give verbal and written safety-net advice, taking into account the parents capacity to appreciate if the child becomes unwell they should return for further assessment

Companion Documents

- Safety-net information leaflet for parents / carers

Definition of terms

Clotting: Coagulation studies
CRP: C-reactive protein
CSF: Cerebrospinal fluid
DIC: Disseminated intravascular coagulation
ED: Emergency department
FBC: Full blood count
HSP: Henoch-Schonlein purpura
ICU: Intensive care unit
IM: Intramuscular
ITP: Immune thrombocytopenia
LP: Lumbar puncture
NAI: Non-accidental injury
NBR: Non-blanching rash
PCR: Polymerase chain reaction
SBI: Serious bacterial infection
SVC: Superior vena cava
U&E: Urea & electrolytes

3. Education and Training

None

4. Monitoring Compliance

None

5. Supporting References

1. Wells LC, Smith JC, Weston VC, Collier J, Rutter N. The child with a non-blanching rash: how likely is meningococcal disease?. Arch Dis Child. 2001;85(3):218-222
2. Mandl KD, Stack AM, Fleisher GR. Incidence of bacteremia in infants and children with fever and petechiae. J Pediatr. 1997;131(3):398-404
3. Nielsen HE, Andersen EA, Andersen J, et al. Diagnostic assessment of haemorrhagic rash and fever. Arch Dis Child. 2001;85(2):160-165.
4. Brogan PA, Raffles A. The management of fever and petechiae: making sense of rash decisions. Arch Dis Child. 2000;83(6):506-507

5. Riordan FA, Jones L, Clark J; Non-Blanching Rash Audit Group. Validation of two algorithms for managing children with a non-blanching rash. Arch Dis Child. 2016;101(8):709-713
6. Bourke TW, McKenna JP, Coyle PV, Shields MD, Fairley DJ. Diagnostic accuracy of loop-mediated isothermal amplification as a near-patient test for meningococcal disease in children: an observational cohort study. Lancet Infect Dis. 2015;15(5):552-558
7. Burrows NP. Purpura in infants and children. J Am Acad Dermatol. 1998;39(4 Pt 1):661-662.
8. Barut K, Şahin S, Adroviç A, Kasapçopur Ö. Diagnostic approach and current treatment options in childhood vasculitis. Turk Pediatri Ars. 2015;50(4):194-205. Published 2015 Dec 1
9. Buchanan GR. Immune thrombocytopenia during childhood: new approaches to classification and management. J Pediatr. 2014;165(3):437-439
10. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168-186
11. Tilden W, Valliani S. Severe thrombocytopenia and recurrent epistaxis associated with primary Epstein-Barr virus infection. BMJ Case Rep. 2015;2015:bcr2014208018. Published 2015 Apr 9
12. Moulis G, Sommet A, Sailler L, Lapeyre-Mestre M, Montastruc JL; French Association Of Regional Pharmacovigilance Centers. Drug-induced immune thrombocytopenia: a descriptive survey in the French PharmacoVigilance database. Platelets. 2012;23(6):490-494
13. Chaudhry R, Wegner R, Zaki JF, et al. Incidence and Outcomes of Heparin-Induced Thrombocytopenia in Patients Undergoing Vascular Surgery. J Cardiothorac Vasc Anesth. 2017;31(5):1751-1757.
14. Bangia AV, Kamath N, Mohan V. Ranitidine-induced thrombocytopenia: A rare drug reaction. Indian J Pharmacol. 2011;43(1):76-77
15. Clarke RT, Van den Bruel A, Bankhead C, Mitchell CD, Phillips B, Thompson MJ. Clinical presentation of childhood leukaemia: a systematic review and meta-analysis. Arch Dis Child. 2016;101(10):894-901
16. Waterfield T, Maney JA, Fairley D, et al. Validating clinical practice guidelines for the management of children with non-blanching rashes in the UK (PiC): a prospective, multicentre cohort study [published online ahead of print, 2020 Nov 10]. Lancet Infect Dis. 2020;S1473-3099(20)30474-6
17. Downes AJ, Crossland DS, Mellon AF. Prevalence and distribution of petech*Brief*

6. Key Words

Disseminated intravascular coagulation (DIC), Henoch-Schonlein purpura (HSP), Meningococcal disease, Sepsis

---

The Trust recognises the diversity of the local community it serves. Our aim therefore is to provide a safe environment free from discrimination and treat all individuals fairly with dignity and appropriately according to their needs.

As part of its development, this policy and its impact on equality have been reviewed and no detriment was identified.

Stakeholders;

1. Dr. Shane Fitzgerald, Paediatric Emergency Medicine Grid Trainee at UHL
2. Dr. Razi Paracha, Consultant Paediatrician at UHL
3. Dr. Amy Atkinson, PEM Consultant at UHL
4. Prof Damian Roland, PEM Consultant at UHL

Contact and review details	
Guideline Lead (Name and Title) Shane Fitzgerald Paediatric Education OOPE	**Executive Lead** **Chief Medical Officer**
Details of Changes made during review: **April 2024** **New document**	